<table id="table5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5 Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or on Predicted Interaction with INVIRASE/ritonavir</caption>
<col align="left" valign="top" width="33%"></col>
<col align="left" valign="top" width="33%"></col>
<col align="left" valign="top" width="34%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Concomitant Drug Class:<br/>Drug Name</th>
<th align="center" stylecode="Rrule">Effect on  Concentration of Saquinavir or Concomitant Drug</th>
<th align="center" stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-Antiviral Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
<br/>Delavirdine<footnote id="t5ftb">INVIRASE/ritonavir interaction has not been evaluated.</footnote>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/> <br/> Effect on delavirdine is not well established</td>
<td stylecode="Rrule">Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
<br/>Efavirenz<footnote id="t5fta">See <content stylecode="bold">
<linkhtml href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</linkhtml>
</content>, <content stylecode="bold">
<linkhtml href="#table2">Table 2</linkhtml>
</content> and <content stylecode="bold">
<linkhtml href="#table3">Table 3</linkhtml>
</content> for magnitude of interactions.</footnote>,<br/>nevirapine<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>↔ Efavirenz</td>
<td stylecode="Rrule">Appropriate doses of the combination of efavirenz or nevirapine and INVIRASE/ritonavir (1000/100 mg bid) with respect to safety and efficacy have not been established. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV protease inhibitor:</content>
<br/>Atazanavir<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">
<content stylecode="bold">INVIRASE/ritonavir</content>
<br/>↑ Saquinavir<br/>↑ Ritonavir<br/>↔ Atazanavir</td>
<td stylecode="Rrule">Appropriate dosing recommendations for this combination, with respect to efficacy and safety, have not been established. When 1600 mg INVIRASE/100 mg ritonavir and 300 mg atazanavir were coadministered, plasma concentrations of saquinavir and ritonavir were increased.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV protease inhibitor:</content>
<br/>Indinavir<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/> <br/> Effect on indinavir is not well established</td>
<td stylecode="Rrule">Appropriate doses of the combination of indinavir and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV protease inhibitor:</content>
<br/> Lopinavir/ritonavir<footnoteref idref="t5fta"></footnoteref> (coformulated capsule)</td>
<td stylecode="Rrule">↔ Saquinavir<br/>↔ Lopinavir<br/>↓ Ritonavir</td>
<td stylecode="Rrule">Evidence from several clinical trials indicates that saquinavir concentrations achieved with the saquinavir and lopinavir/ritonavir combination are similar to those achieved following saquinavir/ritonavir 1000/100 mg. The recommended dose for this combination is saquinavir 1000 mg plus lopinavir/ritonavir 400/100 mg bid.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV protease inhibitor:</content>
<br/>Tipranavir/ritonavir<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Combining saquinavir with tipranavir/ritonavir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV fusion inhibitor:</content>
<br/>Enfuvirtide<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">Saquinavir soft gel capsules/ritonavir<br/>↔ enfuvirtide</td>
<td stylecode="Rrule">No clinically significant interaction was noted from a study in 12 HIV patients who received enfuvirtide concomitantly with saquinavir soft gel capsules/ritonavir 1000/100 mg bid. No dose adjustments are required.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>Lidocaine (systemic)<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↑ Antiarrhythmics</td>
<td stylecode="Rrule">Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics given with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulant:</content>
<br/>Warfarin<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↑ Warfarin</td>
<td stylecode="Rrule">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>Carbamazepine<footnoteref idref="t5ftb"></footnoteref>, phenobarbital<footnoteref idref="t5ftb"></footnoteref>, phenytoin<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/> <br/>Effect on carbamazepine, phenobarbital, and phenytoin is not well established</td>
<td stylecode="Rrule">Use with caution, saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-infective:</content>
<br/>Clarithromycin<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/>↑ Clarithromycin<br/>
</td>
<td stylecode="Rrule">Appropriate doses of the combination of clarithromycin and INVIRASE/ritonavir with respect to safety and efficacy have not been established.<br/> <br/> Due to the known effect of ritonavir on clarithromycin concentrations, the following dose adjustments are recommended: <br/> For patients with renal impairment, the following dosage adjustments should be considered:<br/> <list>
<item>For patients with CL<sub>CR</sub> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</item>
<item>For patients with CL<sub>CR</sub> &lt;30 mL/min the dose of clarithromycin should be decreased by 75%.</item>
</list>No dose adjustment for patients with normal renal function is necessary.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungal:</content>
<br/>Ketoconazole<footnoteref idref="t5fta"></footnoteref>, itraconazole<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↔ Saquinavir<br/>↔ Ritonavir<br/>↑ Ketoconazole</td>
<td stylecode="Rrule">Appropriate doses of the combination of ketoconazole or itraconazole and INVIRASE/ritonavir with respect to safety and efficacy have not been established. When INVIRASE/ritonavir and ketoconazole are coadministered, plasma concentration of ketoconazole was increased (see <content stylecode="bold">
<linkhtml href="#table2">Table 2</linkhtml>
</content>). Hence, doses of ketoconazole &gt; 200 mg/day are not recommended. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterial:</content>
<br/>Rifabutin<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>↑ Rifabutin</td>
<td stylecode="Rrule">Appropriate doses of the combination of rifabutin and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Benzodiazepines<footnoteref idref="t5ftb"></footnoteref>:</content>
<br/>Alprazolam, clorazepate, diazepam, flurazepam</td>
<td stylecode="Rrule">↑ Benzodiazepines</td>
<td stylecode="Rrule">Clinical significance is unknown; however, a decrease in benzodiazepine dose may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Benzodiazepine</content>
<footnoteref idref="t5ftb"></footnoteref>
<content stylecode="bold">:</content>
<br/> Intravenously administered Midazolam</td>
<td stylecode="Rrule">↑ Midazolam</td>
<td stylecode="Rrule">Midazolam is extensively metabolized by CYP3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration. Therefore, INVIRASE should not be given with orally administered midazolam [see <linkhtml href="#CONTRAINDICATIONS">Contraindications (4)</linkhtml>]. If INVIRASE is coadministered with parenteral midazolam, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustment should be considered. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium channel blockers</content>
<footnoteref idref="t5ftb"></footnoteref>
<content stylecode="bold">:</content>
<br/> Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine</td>
<td stylecode="Rrule">↑ Calcium channel blockers</td>
<td stylecode="Rrule">Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid:</content>
<br/> Dexamethasone<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Use with caution, saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Digitalis Glycosides: </content>
<br/>Digoxin<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↑ Digoxin<br/> <br/> Increases in serum digoxin concentration were greater in female subjects as compared to male subjects when digoxin was coadministered with INVIRASE/ritonavir.</td>
<td stylecode="Rrule">Concomitant use of INVIRASE/ritonavir with digoxin results in a significant increase in serum concentrations of digoxin. Caution should be exercised when INVIRASE/ritonavir and digoxin are coadministered; serum digoxin concentrations should be monitored and the dose of digoxin may need to be reduced when coadministered with INVIRASE/ritonavir (see <content stylecode="bold">
<linkhtml href="#WARNINGS">WARNINGS</linkhtml>
</content>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Inhaled/nasal steroid:</content>
<br/> Fluticasone<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">
<content stylecode="bold">INVIRASE/ritonavir</content>
<br/>↑ Fluticasone</td>
<td stylecode="Rrule">Concomitant use of fluticasone propionate and INVIRASE/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Coadministration of fluticasone propionate and INVIRASE/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects (see <content stylecode="bold">
<linkhtml href="#WARNINGS">WARNINGS</linkhtml>
</content>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA reductase inhibitors</content>
<footnoteref idref="t5ftb"></footnoteref>
<content stylecode="bold">:</content>
<br/>Atorvastatin, rosuvastatin</td>
<td stylecode="Rrule">↑ Atorvastatin<br/>↑ Rosuvastatin  </td>
<td stylecode="Rrule">Use lowest possible dose of atorvastatin or rosuvastatin  with careful monitoring, or consider other HMG-CoA reductase inhibitors such as fluvastatin in combination with Invirase/ritonavir (see <content stylecode="bold">
<linkhtml href="#WARNINGS">WARNINGS</linkhtml>
</content>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressants</content>
<footnoteref idref="t5ftb"></footnoteref>
<content stylecode="bold">:</content>
<br/> Cyclosporine, tacrolimus, rapamycin</td>
<td stylecode="Rrule">↑ Immunosuppressants </td>
<td stylecode="Rrule">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic analgesic:</content>
<br/> Methadone<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↓ Methadone</td>
<td stylecode="Rrule">Dosage of methadone may need to be increased when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Oral contraceptives:</content>
<br/> Ethinyl estradiol<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↓ Ethinyl estradiol</td>
<td stylecode="Rrule">Alternative or additional contraceptive measures should be used when estrogen-based oral contraceptives and INVIRASE/ritonavir are coadministered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">PDE5 inhibitors</content>
<content stylecode="bold">(phosphodiesterase type 5 inhibitors):</content>
<br/> Sildenafil<footnoteref idref="t5fta"></footnoteref>, vardenafil<footnoteref idref="t5ftb"></footnoteref>, tadalafil<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↑ Sildenafil<br/>↔ Saquinavir<br/> <br/> ↑ Vardenafil<br/> ↑ Tadalafil</td>
<td stylecode="Rrule">Use sildenafil with caution at reduced doses of 25 mg every 48 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br/> <br/> Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br/> <br/> Use tadalafil with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antidepressant:</content>
<br/>Trazodone <footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↑ Trazodone</td>
<td stylecode="Rrule">Concomitant use of trazodone and INVIRASE/ritonavir may increase plasma concentration of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as INVIRASE/ritonavir, the combination should be used with caution and lower dose of trazodone should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Tricyclic antidepressants</content>
<footnoteref idref="t5ftb"></footnoteref>
<content stylecode="bold">: </content>Amitriptyline, imipramine</td>
<td stylecode="Rrule">↑ Tricyclics</td>
<td stylecode="Rrule">Therapeutic concentration monitoring is recommended for tricyclic antidepressants when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Proton pump inhibitors: </content>Omeprazole<footnoteref idref="t5fta"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir</td>
<td stylecode="Rrule">When INVIRASE/ritonavir is co-administered with omeprazole, saquinavir concentrations are increased significantly. If omeprazole or another proton pump inhibitor is taken concomitantly with INVIRASE/ritonavir, caution is advised and monitoring for potential saquinavir toxicities is recommended, particularly  gastrointestinal symptoms,  increased triglycerides, and deep vein thrombosis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Herbal Products:</content>
<br/> St. John's wort<footnoteref idref="t5ftb"></footnoteref> (hypericum perforatum)</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors (see <content stylecode="bold">
<linkhtml href="#WARNINGS">WARNINGS</linkhtml>
</content>).</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Garlic Capsules<footnoteref idref="t5ftb"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Coadministration of garlic capsules and saquinavir is not recommended due to the potential for garlic capsules to induce the metabolism of saquinavir which may result in sub-therapeutic saquinavir concentrations. </td>
</tr>
</tbody>
</table>